GSK RSV vaccine shows potential to protect adults 50 to 59

The results suggest that GSK's shot could help protect a wider population from RSV, which causes thousands of hospitalizations and deaths each year.

Related Keywords

United Kingdom ,Japan ,United States ,Americans ,British ,Tony Wood ,Drug Administration ,Pfizer ,Glaxosmithkline ,Business ,Biotechnology ,Biotech And Pharmaceuticals ,Pharmaceuticals ,Health Care Industry ,Pfizer Inc ,Gsk Plc ,Social Issues ,Breaking News ,Respiratory Syncytial Virus ,Immunizations ,Business News ,